{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:10:43Z","timestamp":1789060243685,"version":"build-2803163510"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Transl. Res."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s12265-026-10841-0","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:05:16Z","timestamp":1789059916000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Self-Nanoemulsifying Drug Delivery Systems for Cardiovascular Therapeutics: Formulation Strategies, Pharmacokinetic Enhancement and Precision-Oriented Translation"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6352-0535","authenticated-orcid":false,"given":"Rohit","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"issue":"4","key":"10841_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3390\/cells13040353","volume":"13","author":"M Camacho-Encina","year":"2024","unstructured":"Camacho-Encina M, Booth LK, Redgrave RE, Folaranmi O, Spyridopoulos I, Richardson GD. Cellular senescence, mitochondrial dysfunction, and their link to cardiovascular disease. Cells. 2024;13(4):353.","journal-title":"Cells"},{"issue":"14","key":"10841_CR2","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.jacc.2012.03.074","volume":"60","author":"DS Celermajer","year":"2012","unstructured":"Celermajer DS, Chow CK, Marijon E, Anstey NM, Woo KS. Cardiovascular disease in the developing world: prevalences, patterns, and the potential of early disease detection. J Am Coll Cardiol. 2012;60(14):1207\u201316. https:\/\/doi.org\/10.1016\/j.jacc.2012.03.074.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10841_CR3","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","volume":"133","author":"RJ Koene","year":"2016","unstructured":"Koene RJ, Prizment AE, Blaes A, Konety SH. Shared Risk Factors in Cardiovascular Disease and Cancer. Circulation. 2016;133(11):1104\u201314. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.020406.","journal-title":"Circulation"},{"issue":"38","key":"10841_CR4","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.2174\/1381612825666190925163827","volume":"25","author":"GD Flora","year":"2019","unstructured":"Flora GD, Nayak MK. A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes. Curr Pharm Des. 2019;25(38):4063\u201384. https:\/\/doi.org\/10.2174\/1381612825666190925163827.","journal-title":"Curr Pharm Des"},{"key":"10841_CR5","first-page":"e65","volume":"150","author":"KJ Maddox","year":"2024","unstructured":"Maddox KJ, Elkind MS, Aparicio HJ, Commodore-Mensah Y, de Ferranti SD, Dowd WN, et al. Forecasting the burden of cardiovascular disease and stroke in the United States through 2050\u2014prevalence of risk factors and disease: a presidential advisory from the American Heart Association. Circulation. 2024;150:e65\u201388.","journal-title":"Circulation"},{"issue":"7","key":"10841_CR6","doi-asserted-by":"publisher","first-page":"e033428","DOI":"10.1161\/JAHA.123.033428","volume":"13","author":"S Khadke","year":"2024","unstructured":"Khadke S, Kumar A, Al-Kindi S, Rajagopalan S, Kong Y, Nasir K, et al. Association of Environmental Injustice and Cardiovascular Diseases and Risk Factors in the United States. J Am Heart Assoc. 2024;13(7):e033428. https:\/\/doi.org\/10.1161\/JAHA.123.033428.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10841_CR7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1186\/s12889-024-18316-0","volume":"24","author":"YA Al-Ajlouni","year":"2024","unstructured":"Al-Ajlouni YA, Al Ta\u2019ani O, Shamaileh G, Nagi Y, Tanashat M, Al-Bitar F, et al. The burden of Cardiovascular diseases in Jordan: a longitudinal analysis from the global burden of disease study, 1990\u20132019. BMC Public Health. 2024;24(1):879. https:\/\/doi.org\/10.1186\/s12889-024-18316-0.","journal-title":"BMC Public Health"},{"key":"10841_CR8","doi-asserted-by":"publisher","first-page":"e078523","DOI":"10.1136\/bmj-2023-078523","volume":"385","author":"N Conrad","year":"2024","unstructured":"Conrad N, Molenberghs G, Verbeke G, Zaccardi F, Lawson C, Friday JM, et al. Trends in cardiovascular disease incidence among 22 million people in the UK over 20 years: population based study. BMJ. 2024;385:e078523. https:\/\/doi.org\/10.1136\/bmj-2023-078523.","journal-title":"BMJ"},{"issue":"1","key":"10841_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/cvr\/cvad176","volume":"120","author":"R Lopez-Bueno","year":"2024","unstructured":"Lopez-Bueno R, Nunez-Cortes R, Calatayud J, Salazar-Mendez J, Petermann-Rocha F, Lopez-Gil JF, et al. Global prevalence of cardiovascular risk factors based on the Life\u2019s Essential 8 score: an overview of systematic reviews and meta-analysis. Cardiovasc Res. 2024;120(1):13\u201333. https:\/\/doi.org\/10.1093\/cvr\/cvad176.","journal-title":"Cardiovasc Res"},{"key":"10841_CR10","doi-asserted-by":"publisher","first-page":"1008335","DOI":"10.3389\/fcvm.2022.1008335","volume":"9","author":"NW Minja","year":"2022","unstructured":"Minja NW, Nakagaayi D, Aliku T, Zhang W, Ssinabulya I, Nabaale J, et al. Cardiovascular diseases in Africa in the twenty-first century: Gaps and priorities going forward. Front Cardiovasc Med. 2022;9:1008335. https:\/\/doi.org\/10.3389\/fcvm.2022.1008335.","journal-title":"Front Cardiovasc Med"},{"key":"10841_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3389\/fbioe.2019.00489","volume":"7","author":"Y Deng","year":"2019","unstructured":"Deng Y, Zhang X, Shen H, He Q, Wu Z, Liao W, et al. Application of the Nano-Drug Delivery System in Treatment of Cardiovascular Diseases. Front Bioeng Biotechnol. 2019;7:489. https:\/\/doi.org\/10.3389\/fbioe.2019.00489.","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"10841_CR12","doi-asserted-by":"publisher","first-page":"2335469","DOI":"10.1080\/19336950.2024.2335469","volume":"18","author":"T Theiner","year":"2024","unstructured":"Theiner T, Ortner NJ, Oberacher H, Stojanovic G, Tuluc P, Striessnig J. Novel protocol for multiple-dose oral administration of the L-type Ca(2+) channel blocker isradipine in mice: A dose-finding pharmacokinetic study. Channels (Austin). 2024;18(1):2335469. https:\/\/doi.org\/10.1080\/19336950.2024.2335469.","journal-title":"Channels (Austin)"},{"issue":"4","key":"10841_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/phar.2380","volume":"40","author":"W Liu","year":"2020","unstructured":"Liu W, Yan T, Chen K, Yang L, Benet LZ, Zhai S. Predicting interactions between rifampin and antihypertensive drugs using the Biopharmaceutics Drug Disposition Classification System. Pharmacotherapy: J Hum Pharmacol Drug Therapy. 2020;40(4):274\u201390.","journal-title":"Pharmacotherapy: J Hum Pharmacol Drug Therapy"},{"issue":"2","key":"10841_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2165\/00003495-199244020-00008","volume":"44","author":"PA Todd","year":"1992","unstructured":"Todd PA, Faulds D, Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs. 1992;44(2):251\u201377. https:\/\/doi.org\/10.2165\/00003495-199244020-00008.","journal-title":"Drugs"},{"issue":"7","key":"10841_CR15","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.3390\/pharmaceutics14071474","volume":"14","author":"LM Fuhr","year":"2022","unstructured":"Fuhr LM, Marok FZ, Mees M, Mahfoud F, Selzer D, Lehr T. A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling. Pharmaceutics. 2022;14(7):1474. https:\/\/doi.org\/10.3390\/pharmaceutics14071474.","journal-title":"Pharmaceutics"},{"issue":"3","key":"10841_CR16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2165\/00002512-199506030-00006","volume":"6","author":"W Muck","year":"1995","unstructured":"Muck W, Ahr G, Kuhlmann J. Nimodipine. Potential for drug-drug interactions in the elderly. Drugs Aging. 1995;6(3):229\u201342. https:\/\/doi.org\/10.2165\/00002512-199506030-00006.","journal-title":"Drugs Aging"},{"issue":"5","key":"10841_CR17","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1067\/mcp.2002.128127","volume":"72","author":"P Blardi","year":"2002","unstructured":"Blardi P, Urso R, De Lalla A, Volpi L, Perri TD, Auteri A. Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. Clin Pharmacol Ther. 2002;72(5):556\u201361. https:\/\/doi.org\/10.1067\/mcp.2002.128127.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10841_CR18","doi-asserted-by":"publisher","first-page":"e7186","DOI":"10.1002\/ccr3.7186","volume":"11","author":"G Timour","year":"2023","unstructured":"Timour G, Frederic V, Olivier S, Shango DN. Nicardipine-induced acute respiratory failure: Case report and literature review. Clin Case Rep. 2023;11(5):e7186. https:\/\/doi.org\/10.1002\/ccr3.7186.","journal-title":"Clin Case Rep"},{"issue":"20","key":"10841_CR19","doi-asserted-by":"publisher","first-page":"8812","DOI":"10.1039\/d4dt00818a","volume":"53","author":"SS Hossain","year":"2024","unstructured":"Hossain SS, Volkmer D, Biswas S. Naphthalimide functionalized metal-organic framework for rapid and nanomolar level detection of hydrazine and anti-hypertensive drug nicardipine. Dalton Trans. 2024;53(20):8812\u201322. https:\/\/doi.org\/10.1039\/d4dt00818a.","journal-title":"Dalton Trans"},{"issue":"11\u201312","key":"10841_CR20","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1080\/17425255.2024.2402481","volume":"20","author":"A Ayub","year":"2024","unstructured":"Ayub A, Zamir A, Imran I, Saeed H, Majeed A, Aziz M, et al. Clinical pharmacokinetics and pharmacodynamics of nicardipine; a systematic review. Expert Opin Drug Metab Toxicol. 2024;20(11\u201312):1053\u201367. https:\/\/doi.org\/10.1080\/17425255.2024.2402481.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"10841_CR21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1208\/s12249-020-01772-3","volume":"21","author":"F Li","year":"2020","unstructured":"Li F, Fei Q, Mao D, Si Q, Dai M, Ma Q, et al. Comparative Pharmacokinetics of Nimodipine in Rat Plasma and Tissues Following Intraocular, Intragastric, and Intravenous Administration. AAPS PharmSciTech. 2020;21(6):234. https:\/\/doi.org\/10.1208\/s12249-020-01772-3.","journal-title":"AAPS PharmSciTech"},{"key":"10841_CR22","doi-asserted-by":"publisher","first-page":"174038","DOI":"10.1016\/j.ejphar.2021.174038","volume":"900","author":"PJ Morone","year":"2021","unstructured":"Morone PJ, Yan W, Adcock J, Komalavilas P, Mocco J, Thompson RC, et al. Vasorelaxing cell permeant phosphopeptide mimetics for subarachnoid hemorrhage. Eur J Pharmacol. 2021;900:174038. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174038.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10841_CR23","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s13346-020-00775-8","volume":"10","author":"RB Chavan","year":"2020","unstructured":"Chavan RB, Lodagekar A, Yadav B, Shastri NR. Amorphous solid dispersion of nisoldipine by solvent evaporation technique: preparation, characterization, in vitro, in vivo evaluation, and scale up feasibility study. Drug Deliv Transl Res. 2020;10(4):903\u201318. https:\/\/doi.org\/10.1007\/s13346-020-00775-8.","journal-title":"Drug Deliv Transl Res"},{"issue":"5","key":"10841_CR24","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.neuchi.2021.02.005","volume":"67","author":"D Viderman","year":"2021","unstructured":"Viderman D, Sarria-Santamera A, Bilotta F. Side effects of continuous intra-arterial infusion of nimodipine for management of resistant cerebral vasospasm in subarachnoid hemorrhage patients: A systematic review. Neurochirurgie. 2021;67(5):461\u20139. https:\/\/doi.org\/10.1016\/j.neuchi.2021.02.005.","journal-title":"Neurochirurgie"},{"issue":"5","key":"10841_CR25","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/01.str.30.5.1056","volume":"30","author":"J Topouchian","year":"1999","unstructured":"Topouchian J, Asmar R, Sayegh F, Rudnicki A, Benetos A, Bacri AM, et al. Changes in arterial structure and function under trandolapril-verapamil combination in hypertension. Stroke. 1999;30(5):1056\u201364. https:\/\/doi.org\/10.1161\/01.str.30.5.1056.","journal-title":"Stroke"},{"issue":"19","key":"10841_CR26","doi-asserted-by":"publisher","first-page":"5969","DOI":"10.3390\/jcm13195969","volume":"13","author":"S Kumagai","year":"2024","unstructured":"Kumagai S, Sambe T, Shibata K, Mizukami T, Morohoshi H, Ryu K, et al. Comparative Analysis of Verapamil Pharmacokinetics: Evaluating the Impact of Simple Suspension and Crushing Administration Methods. J Clin Med. 2024;13(19):5969.","journal-title":"J Clin Med"},{"key":"10841_CR27","doi-asserted-by":"publisher","first-page":"1403649","DOI":"10.3389\/fphar.2024.1403649","volume":"15","author":"H Xia","year":"2024","unstructured":"Xia H, Xu X, Chen J, Wu H, Shen Y, Chen X, et al. Inhibitory effects of calcium channel blockers nisoldipine and nimodipine on ivacaftor metabolism and their underlying mechanism. Front Pharmacol. 2024;15:1403649. https:\/\/doi.org\/10.3389\/fphar.2024.1403649.","journal-title":"Front Pharmacol"},{"key":"10841_CR28","volume-title":"Nisoldipine. StatPearls","author":"G Sidhu","year":"2024","unstructured":"Sidhu G, Patel P, Hashmi MF. Nisoldipine. StatPearls. Treasure Island (FL): StatPearls Publishing; 2024."},{"issue":"10","key":"10841_CR29","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.3390\/pr12102060","volume":"12","author":"D Unnikrishnan Meenakshi","year":"2024","unstructured":"Unnikrishnan Meenakshi D, Narde GK, Ahuja A, Akhtar MJ, Khan SA. Role of Natural Phytoconstituents as a Potential Bioenhancer of Anti-Cancer and Anti-Microbial Agents: Spotlight on the Mechanism of Action, Clinical Studies and Patents. Processes. 2024;12(10):2060.","journal-title":"Processes"},{"issue":"6","key":"10841_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/bdd.2336","volume":"43","author":"SH Elewa","year":"2022","unstructured":"Elewa SH, Osman MA, Essa EA, Sultan AA. Intestinal absorption pathways of lisinopril: Mechanistic investigations. Biopharm Drug Dispos. 2022;43(6):233\u201346. https:\/\/doi.org\/10.1002\/bdd.2336.","journal-title":"Biopharm Drug Dispos"},{"key":"10841_CR31","doi-asserted-by":"publisher","first-page":"1166973","DOI":"10.3389\/fnins.2023.1166973","volume":"17","author":"J Ghalayini","year":"2023","unstructured":"Ghalayini J, Boulianne GL. Deciphering mechanisms of action of ACE inhibitors in neurodegeneration using Drosophila models of Alzheimer\u2019s disease. Front Neurosci. 2023;17:1166973. https:\/\/doi.org\/10.3389\/fnins.2023.1166973.","journal-title":"Front Neurosci"},{"issue":"7","key":"10841_CR32","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.3390\/molecules27072232","volume":"27","author":"M Kus","year":"2022","unstructured":"Kus M, Gorniak K, Czaklosz P, Olejnik A, Skupin-Mrugalska P, Ibragimow I, et al. Permeability of the Perindopril Arginine under In Vitro Conditions across Caco-2 Monolayer and Biomimetic Phospholipid Membrane. Molecules. 2022;27(7):2232. https:\/\/doi.org\/10.3390\/molecules27072232.","journal-title":"Molecules"},{"key":"10841_CR33","doi-asserted-by":"publisher","first-page":"624515","DOI":"10.3389\/fphys.2021.624515","volume":"12","author":"DS Miotto","year":"2021","unstructured":"Miotto DS, Dionizio A, Jacomini AM, Zago AS, Buzalaf MAR, Amaral SL. Identification of Aortic Proteins Involved in Arterial Stiffness in Spontaneously Hypertensive Rats Treated With Perindopril:A Proteomic Approach. Front Physiol. 2021;12:624515. https:\/\/doi.org\/10.3389\/fphys.2021.624515.","journal-title":"Front Physiol"},{"issue":"3","key":"10841_CR34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.51847\/JQC55C3x8x","volume":"12","author":"IS Jaafar","year":"2022","unstructured":"Jaafar IS, Sabar MH, Radhi AA. Factors controlling development of benazepril mouth dissolving drug delivery system. J Adv Pharm Educ Res. 2022;12(3):93\u20139. https:\/\/doi.org\/10.51847\/JQC55C3x8x.","journal-title":"J Adv Pharm Educ Res"},{"key":"10841_CR35","doi-asserted-by":"publisher","first-page":"111263","DOI":"10.1016\/j.mce.2021.111263","volume":"529","author":"A Vergara","year":"2021","unstructured":"Vergara A, Jacobs-Cacha C, Molina-Van den Bosch M, Dominguez-Baez P, Benito B, Garcia-Carro C, et al. Effect of ramipril on kidney, lung and heart ACE2 in a diabetic mice model. Mol Cell Endocrinol. 2021;529:111263. https:\/\/doi.org\/10.1016\/j.mce.2021.111263.","journal-title":"Mol Cell Endocrinol"},{"issue":"7","key":"10841_CR36","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1080\/03007995.2024.2362276","volume":"40","author":"G Desideri","year":"2024","unstructured":"Desideri G, Pegoraro V, Cipelli R, Ripellino C, Miroddi M, Meto S, et al. Extemporaneous combination therapy with nebivolol\/ramipril for the treatment of hypertension: a real-world evidence study in Europe. Curr Med Res Opin. 2024;40(7):1093\u2013102. https:\/\/doi.org\/10.1080\/03007995.2024.2362276.","journal-title":"Curr Med Res Opin"},{"key":"10841_CR37","doi-asserted-by":"publisher","first-page":"1390547","DOI":"10.3389\/fcvm.2024.1390547","volume":"11","author":"L Hejnova","year":"2024","unstructured":"Hejnova L, Drastichova Z, Boro\u0161 A, Hrdlicka J, Behuliak M, Neckar J, et al. Modulation of left ventricular hypertrophy in spontaneously hypertensive rats by acetylcholinesterase and ACE inhibitors: physiological, biochemical, and proteomic studies. Front Cardiovasc Med. 2024;11:1390547. https:\/\/doi.org\/10.3389\/fcvm.2024.1390547.","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"10841_CR38","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40119-024-00381-6","volume":"13","author":"M Sobhy","year":"2024","unstructured":"Sobhy M, Eletriby A, Ragy H, Kandil H, Saleh MA, Farag N, et al. ACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP Foundation. Cardiol Ther. 2024;13(4):707\u201336. https:\/\/doi.org\/10.1007\/s40119-024-00381-6.","journal-title":"Cardiol Ther"},{"key":"10841_CR39","unstructured":"Alessi K, Patel P, Parmar M. Fosinopril. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2024. StatPearls Publishing LLC; 2024."},{"issue":"6","key":"10841_CR40","doi-asserted-by":"publisher","first-page":"460","DOI":"10.2165\/00003088-199732060-00003","volume":"32","author":"H Shionoiri","year":"1997","unstructured":"Shionoiri H, Naruse M, Minamisawa K, Ueda S, Himeno H, Hiroto S, et al. Fosinopril. Clinical pharmacokinetics and clinical potential. Clin Pharmacokinet. 1997;32(6):460\u201380. https:\/\/doi.org\/10.2165\/00003088-199732060-00003.","journal-title":"Clin Pharmacokinet"},{"issue":"20","key":"10841_CR41","doi-asserted-by":"publisher","first-page":"22H","DOI":"10.1016\/0002-9149(93)91051-i","volume":"72","author":"R Guthrie","year":"1993","unstructured":"Guthrie R. Fosinopril: an overview. Am J Cardiol. 1993;72(20):22H. https:\/\/doi.org\/10.1016\/0002-9149(93)91051-i.","journal-title":"Am J Cardiol"},{"issue":"2","key":"10841_CR42","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4155\/tde-2016-0063","volume":"8","author":"N Dudhipala","year":"2017","unstructured":"Dudhipala N, Veerabrahma K. Candesartan cilexetil loaded nanodelivery systems for improved oral bioavailability. Ther Deliv. 2017;8(2):79\u201388. https:\/\/doi.org\/10.4155\/tde-2016-0063.","journal-title":"Ther Deliv"},{"issue":"8","key":"10841_CR43","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/ajhp\/57.8.739","volume":"57","author":"S See","year":"2000","unstructured":"See S, Stirling AL. Candesartan cilexetil: an angiotensin II-receptor blocker. Am J Health Syst Pharm. 2000;57(8):739\u201346. https:\/\/doi.org\/10.1093\/ajhp\/57.8.739.","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"10841_CR44","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/1470320310391503","volume":"12","author":"Z Zhenfeng","year":"2011","unstructured":"Zhenfeng Z, Huilan S, Junya J, Dong L, Shan L. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. J Renin Angiotensin Aldosterone Syst. 2011;12(3):365\u201374. https:\/\/doi.org\/10.1177\/1470320310391503.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"5","key":"10841_CR45","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2165\/00003495-199855050-00011","volume":"55","author":"KJ McClellan","year":"1998","unstructured":"McClellan KJ, Balfour JA, Eprosartan. Drugs. 1998;55(5):713\u20138. https:\/\/doi.org\/10.2165\/00003495-199855050-00011. discussion 9\u201320.","journal-title":"Drugs"},{"key":"10841_CR46","volume-title":"Clinical and Research Information on Drug-Induced Liver Injury","author":"Eprosartan","year":"2012","unstructured":"Eprosartan, LiverTox. Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012."},{"issue":"16","key":"10841_CR47","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.2165\/00003495-200565160-00012","volume":"65","author":"GW Robins","year":"2005","unstructured":"Robins GW, Scott LJ. Eprosartan: a review of its use in the management of hypertension. Drugs. 2005;65(16):2355\u201377. https:\/\/doi.org\/10.2165\/00003495-200565160-00012.","journal-title":"Drugs"},{"issue":"3","key":"10841_CR48","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1185\/030079902125000499","volume":"18","author":"H McIntyre","year":"2002","unstructured":"McIntyre H, Costa FV, Dusing R, Ambrosioni E, Gerth W. The role of losartan in cost-effective hypertension control. Curr Med Res Opin. 2002;18(3):139\u201345. https:\/\/doi.org\/10.1185\/030079902125000499.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10841_CR49","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1742-1241.2011.02633.x","volume":"65","author":"AM Grosso","year":"2011","unstructured":"Grosso AM, Bodalia PN, Macallister RJ, Hingorani AD, Moon JC, Scott MA. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis. Int J Clin Pract. 2011;65(3):253\u201363. https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02633.x.","journal-title":"Int J Clin Pract"},{"key":"10841_CR50","doi-asserted-by":"publisher","first-page":"174911","DOI":"10.1016\/j.ejphar.2022.174911","volume":"922","author":"S Shimizu","year":"2022","unstructured":"Shimizu S, Nagao Y, Kurabayashi A, Shimizu T, Higashi Y, Karashima T, et al. Effects of losartan on bladder dysfunction due to aging-related severe hypertension in rats. Eur J Pharmacol. 2022;922:174911. https:\/\/doi.org\/10.1016\/j.ejphar.2022.174911.","journal-title":"Eur J Pharmacol"},{"key":"10841_CR51","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/bs.podrm.2017.02.005","volume":"42","author":"AA Al-Majed","year":"2017","unstructured":"Al-Majed AA, Bakheit AHH, Abdel Aziz HA, Al-Jallal AAM, Olmesartan. Profiles Drug Subst Excip Relat Methodol. 2017;42:241\u201386. https:\/\/doi.org\/10.1016\/bs.podrm.2017.02.005.","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"issue":"1","key":"10841_CR52","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.therap.2020.02.023","volume":"76","author":"A Allaoui","year":"2021","unstructured":"Allaoui A, Marcoux D, Vokaer B, Couturier B. Olmesartan-associated enteropathy: Belgian survey. Therapie. 2021;76(1):58\u201360. https:\/\/doi.org\/10.1016\/j.therap.2020.02.023.","journal-title":"Therapie"},{"issue":"10","key":"10841_CR53","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jchf.2020.06.020","volume":"8","author":"KF Docherty","year":"2020","unstructured":"Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Sacubitril\/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. JACC Heart Fail. 2020;8(10):800\u201310. https:\/\/doi.org\/10.1016\/j.jchf.2020.06.020.","journal-title":"JACC Heart Fail"},{"issue":"46","key":"10841_CR54","doi-asserted-by":"publisher","first-page":"e36098","DOI":"10.1097\/MD.0000000000036098","volume":"102","author":"YG Yoo","year":"2023","unstructured":"Yoo YG, Lim MJ, Kim JS, Jeong HE, Ko H, Shin JY. Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients. Med (Baltim). 2023;102(46):e36098. https:\/\/doi.org\/10.1097\/MD.0000000000036098.","journal-title":"Med (Baltim)"},{"issue":"2","key":"10841_CR55","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/cpdd.56","volume":"3","author":"G Sunkara","year":"2014","unstructured":"Sunkara G, Bende G, Mendonza AE, Solar-Yohay S, Biswal S, Neelakantham S, et al. Bioavailability of valsartan oral dosage forms. Clin Pharmacol Drug Dev. 2014;3(2):132\u20138. https:\/\/doi.org\/10.1002\/cpdd.56.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"10841_CR56","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/bdd.2510010604","volume":"1","author":"J McAinsh","year":"1980","unstructured":"McAinsh J, Simpson WT, Holmes BF, Young J, Ellis SH. Bioavailability of atenolol formulations. Biopharm Drug Dispos. 1980;1(6):323\u201332. https:\/\/doi.org\/10.1002\/bdd.2510010604.","journal-title":"Biopharm Drug Dispos"},{"issue":"2","key":"10841_CR57","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/BF03188723","volume":"7","author":"W Kirch","year":"1982","unstructured":"Kirch W, Gorg KG. Clinical pharmacokinetics of atenolol\u2013a review. Eur J Drug Metab Pharmacokinet. 1982;7(2):81\u201391. https:\/\/doi.org\/10.1007\/BF03188723.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"5","key":"10841_CR58","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1177\/030006058901700503","volume":"17","author":"H Vergin","year":"1989","unstructured":"Vergin H, Nitsche V. Oral bioavailability of atenolol. J Int Med Res. 1989;17(5):417\u201325. https:\/\/doi.org\/10.1177\/030006058901700503.","journal-title":"J Int Med Res"},{"key":"10841_CR59","doi-asserted-by":"publisher","unstructured":"Muhammad A. Acebutolol in hypertension. Pakistan Heart J. 1981;14(4). https:\/\/doi.org\/10.47144\/phj.v14i4.483.","DOI":"10.47144\/phj.v14i4.483"},{"issue":"10","key":"10841_CR60","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1111\/jcpt.13764","volume":"47","author":"S Kalsoom","year":"2022","unstructured":"Kalsoom S, Zamir A, Rehman AU, Ashraf W, Imran I, Saeed H, et al. Clinical pharmacokinetics of nadolol: A systematic review. J Clin Pharm Ther. 2022;47(10):1506\u201316. https:\/\/doi.org\/10.1111\/jcpt.13764.","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"10841_CR61","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1526-4610.1987.hed2708421.x","volume":"27","author":"A Sudilovsky","year":"1987","unstructured":"Sudilovsky A, Elkind AH, Ryan RE, Sr., Saper JR, Stern MA, Meyer JH. Comparative efficacy of nadolol and propranolol in the management of migraine. Headache. 1987;27(8):421\u20136. https:\/\/doi.org\/10.1111\/j.1526-4610.1987.hed2708421.x.","journal-title":"Headache"},{"issue":"44","key":"10841_CR62","doi-asserted-by":"publisher","first-page":"6795","DOI":"10.2174\/1381612823666170927123454","volume":"23","author":"ME Okur","year":"2017","unstructured":"Okur ME, Karantas ID, Okur NU, Siafaka PI. Hypertension in 2017: Update in Treatment and Pharmaceutical Innovations. Curr Pharm Des. 2017;23(44):6795\u2013814. https:\/\/doi.org\/10.2174\/1381612823666170927123454.","journal-title":"Curr Pharm Des"},{"key":"10841_CR63","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/bs.podrm.2017.02.006","volume":"42","author":"AA Al-Majed","year":"2017","unstructured":"Al-Majed AA, Bakheit AHH, Abdel Aziz HA, Alajmi FM, AlRabiah H, Propranolol. Profiles Drug Subst Excip Relat Methodol. 2017;42:287\u2013338. https:\/\/doi.org\/10.1016\/bs.podrm.2017.02.006.","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"issue":"18","key":"10841_CR64","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.4045\/tidsskr.09.1435","volume":"130","author":"KK Guldbakke","year":"2010","unstructured":"Guldbakke KK, Rordam OM, Huldt-Nystrom T, Hanssen HK, Hoivik F. [Propanolol used in treatment of infantile hemangioma]. Tidsskr Nor Laegeforen. 2010;130(18):1822\u20134. https:\/\/doi.org\/10.4045\/tidsskr.09.1435.","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"4","key":"10841_CR65","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/gels8040235","volume":"8","author":"ES Khafagy","year":"2022","unstructured":"Khafagy ES, Abu Lila AS, Sallam NM, Sanad RA, Ahmed MM, Ghorab MM, et al. Preparation and Characterization of a Novel Mucoadhesive Carvedilol Nanosponge: A Promising Platform for Buccal Anti-Hypertensive Delivery. Gels. 2022;8(4):235. https:\/\/doi.org\/10.3390\/gels8040235.","journal-title":"Gels"},{"issue":"1","key":"10841_CR66","doi-asserted-by":"publisher","first-page":"7109","DOI":"10.1038\/s41467-022-34765-w","volume":"13","author":"T Benkel","year":"2022","unstructured":"Benkel T, Zimmermann M, Zeiner J, Bravo S, Merten N, Lim VJY, et al. How carvedilol activates \u03b22-adrenoceptors. Nat Commun. 2022;13(1):7109. https:\/\/doi.org\/10.1038\/s41467-022-34765-w.","journal-title":"Nat Commun"},{"issue":"4","key":"10841_CR67","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/j.1875-9114.1983.tb03252.x","volume":"3","author":"EP MacCarthy","year":"1983","unstructured":"MacCarthy EP, Bloomfield SS. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy. 1983;3(4):193\u2013219. https:\/\/doi.org\/10.1002\/j.1875-9114.1983.tb03252.x.","journal-title":"Pharmacotherapy"},{"issue":"Suppl 2","key":"10841_CR68","first-page":"S89","volume":"8","author":"DA Richards","year":"1979","unstructured":"Richards DA, Prichard BN. Clinical pharmacology of labetalol. Br J Clin Pharmacol. 1979;8(Suppl 2):S89\u201393.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10841_CR69","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/17425255.2022.2129005","volume":"18","author":"A Shahzad Qamar","year":"2022","unstructured":"Shahzad Qamar A, Zamir A, Khalid S, Ashraf W, Imran I, Hussain I, et al. A review on the clinical pharmacokinetics of hydralazine. Expert Opin Drug Metab Toxicol. 2022;18(10):707\u201314. https:\/\/doi.org\/10.1080\/17425255.2022.2129005.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"10841_CR70","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.smj.0000197121.12352.19","volume":"99","author":"SW Finks","year":"2006","unstructured":"Finks SW, Finks AL, Self TH. Hydralazine-induced lupus: maintaining vigilance with increased use in patients with heart failure. South Med J. 2006;99(1):18\u201322. https:\/\/doi.org\/10.1097\/01.smj.0000197121.12352.19.","journal-title":"South Med J"},{"issue":"4","key":"10841_CR71","doi-asserted-by":"publisher","first-page":"147032032097589","DOI":"10.1177\/1470320320975893","volume":"21","author":"Q Sun","year":"2020","unstructured":"Sun Q, Sever P, Amiloride. A review. J Renin Angiotensin Aldosterone Syst. 2020;21(4):1470320320975893. https:\/\/doi.org\/10.1177\/1470320320975893.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"12","key":"10841_CR72","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.3390\/biology10121315","volume":"10","author":"P Bryniarski","year":"2021","unstructured":"Bryniarski P, Nazimek K, Marcinkiewicz J. Immunomodulatory Potential of Diuretics. Biology (Basel). 2021;10(12):1315. https:\/\/doi.org\/10.3390\/biology10121315.","journal-title":"Biology (Basel)"},{"issue":"4","key":"10841_CR73","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/med.21476","volume":"38","author":"P Mladenka","year":"2018","unstructured":"Mladenka P, Applova L, Patocka J, Costa VM, Remiao F, Pourova J, et al. Comprehensive review of cardiovascular toxicity of drugs and related agents. Med Res Rev. 2018;38(4):1332\u2013403. https:\/\/doi.org\/10.1002\/med.21476.","journal-title":"Med Res Rev"},{"key":"10841_CR74","first-page":"473","volume-title":"Self-nanoemulsifying drug delivery systems (SNEDDS) and self-microemulsifying drug delivery systems (SMEDDS) as lipid nanocarriers for improving dissolution rate and bioavailability of poorly soluble drugs","author":"M Krsti\u0107","year":"2018","unstructured":"Krsti\u0107 M, Medarevi\u0107 \u0110, \u0110uri\u0161 J, Ibri\u0107 S. Self-nanoemulsifying drug delivery systems (SNEDDS) and self-microemulsifying drug delivery systems (SMEDDS) as lipid nanocarriers for improving dissolution rate and bioavailability of poorly soluble drugs. Lipid nanocarriers for drug targeting: Elsevier; 2018. pp. 473\u2013508."},{"issue":"1","key":"10841_CR75","doi-asserted-by":"publisher","first-page":"55","DOI":"10.22270\/ajprd.v12i1.1349","volume":"12","author":"VKR Khadam","year":"2024","unstructured":"Khadam VKR, Singh RP, Prajapati D, Yunus M, Prajapat B, Rai SK, et al. An Updated Comprehensive Review on Novel Drug Delivery Systems (NDDS) In the Pharmaceuticals. Asian J Pharm Res Dev. 2024;12(1):55\u201364.","journal-title":"Asian J Pharm Res Dev"},{"issue":"4","key":"10841_CR76","doi-asserted-by":"publisher","first-page":"125","DOI":"10.69613\/3f8m9151","volume":"2","author":"S Tanuku","year":"2024","unstructured":"Tanuku S, Velisila D, Thatraju D, kumar Vadaga A. Nanoemulsion Formulation Strategies for Enhanced Drug Delivery. J Pharma Insights Res. 2024;2(4):125\u201338. https:\/\/doi.org\/10.69613\/3f8m9151.","journal-title":"J Pharma Insights Res"},{"issue":"2","key":"10841_CR77","first-page":"103","volume":"10","author":"RP Jadhav","year":"2020","unstructured":"Jadhav RP, Koli VW, Kamble AB, Bhutkar MA. A review on nanoemulsion. Asian J Res Pharm Sci. 2020;10(2):103\u20138.","journal-title":"Asian J Res Pharm Sci"},{"issue":"16","key":"10841_CR78","doi-asserted-by":"publisher","first-page":"5225","DOI":"10.3390\/molecules27165225","volume":"27","author":"KA Qureshi","year":"2022","unstructured":"Qureshi KA, Mohammed SAA, Khan O, Ali HM, El-Readi MZ, Mohammed HA. Cinnamaldehyde-Based Self-Nanoemulsion (CA-SNEDDS) Accelerates Wound Healing and Exerts Antimicrobial, Antioxidant, and Anti-Inflammatory Effects in Rats\u2019 Skin Burn Model. Molecules. 2022;27(16):5225. https:\/\/doi.org\/10.3390\/molecules27165225.","journal-title":"Molecules"},{"issue":"4","key":"10841_CR79","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2217\/nnm-2016-0336","volume":"12","author":"S Beg","year":"2017","unstructured":"Beg S, Jain S, Kushwah V, Bhatti GK, Sandhu PS, Katare OP, et al. Novel surface-engineered solid lipid nanoparticles of rosuvastatin calcium for low-density lipoprotein-receptor targeting: a Quality by Design-driven perspective. Nanomed (Lond). 2017;12(4):333\u201356. https:\/\/doi.org\/10.2217\/nnm-2016-0336.","journal-title":"Nanomed (Lond)"},{"issue":"3","key":"10841_CR80","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/pharmaceutics8030020","volume":"8","author":"A Nasr","year":"2016","unstructured":"Nasr A, Gardouh A, Ghorab M. Novel Solid Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) for Oral Delivery of Olmesartan Medoxomil: Design, Formulation, Pharmacokinetic and Bioavailability Evaluation. Pharmaceutics. 2016;8(3):20. https:\/\/doi.org\/10.3390\/pharmaceutics8030020.","journal-title":"Pharmaceutics"},{"issue":"2","key":"10841_CR81","doi-asserted-by":"publisher","first-page":"11","DOI":"10.61280\/tjpls.v9i2.81","volume":"9","author":"VERMAA ASIJA","year":"2022","unstructured":"ASIJA VERMAA. Self Nanoemulsifying Drug Delivery System: An Updated Review. Trop J Pharm Life Sci. 2022;9(2):11\u201320.","journal-title":"Trop J Pharm Life Sci"},{"key":"10841_CR82","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.colsurfb.2017.11.064","volume":"162","author":"HA Fathi","year":"2018","unstructured":"Fathi HA, Allam A, Elsabahy M, Fetih G, El-Badry M. Nanostructured lipid carriers for improved oral delivery and prolonged antihyperlipidemic effect of simvastatin. Colloids Surf B Biointerfaces. 2018;162:236\u201345. https:\/\/doi.org\/10.1016\/j.colsurfb.2017.11.064.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"8","key":"10841_CR83","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1208\/s12249-024-02968-7","volume":"25","author":"L Noor","year":"2024","unstructured":"Noor L, Hafeez A, Rahman MA, Vishwakarma KK, Kapoor A, Ara N, et al. Demystifying the Potential of Embelin-Loaded Nanoformulations: a Comprehensive Review. AAPS PharmSciTech. 2024;25(8):249. https:\/\/doi.org\/10.1208\/s12249-024-02968-7.","journal-title":"AAPS PharmSciTech"},{"issue":"6","key":"10841_CR84","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1248\/cpb.c14-00814","volume":"63","author":"KM Hwang","year":"2015","unstructured":"Hwang KM, Park SA, Kim JY, Park CW, Rhee YS, Park ES. Formulation and in Vitro Evaluation of Self-microemulsifying Drug Delivery System Containing Fixed-Dose Combination of Atorvastatin and Ezetimibe. Chem Pharm Bull (Tokyo). 2015;63(6):423\u201330. https:\/\/doi.org\/10.1248\/cpb.c14-00814.","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"21\u201322","key":"10841_CR85","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.drudis.2010.08.007","volume":"15","author":"K Kohli","year":"2010","unstructured":"Kohli K, Chopra S, Dhar D, Arora S, Khar RK. Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discov Today. 2010;15(21\u201322):958\u201365. https:\/\/doi.org\/10.1016\/j.drudis.2010.08.007.","journal-title":"Drug Discov Today"},{"issue":"1","key":"10841_CR86","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/pharmaceutics17010063","volume":"17","author":"P Uttreja","year":"2025","unstructured":"Uttreja P, Karnik I, Adel Ali Youssef A, Narala N, Elkanayati RM, Baisa S, et al. Self-Emulsifying Drug Delivery Systems (SEDDS): Transition from Liquid to Solid-A Comprehensive Review of Formulation, Characterization, Applications, and Future Trends. Pharmaceutics. 2025;17(1):63. https:\/\/doi.org\/10.3390\/pharmaceutics17010063.","journal-title":"Pharmaceutics"},{"issue":"5","key":"10841_CR87","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/17425247.2025.2479759","volume":"22","author":"F Laffleur","year":"2025","unstructured":"Laffleur F, Millotti G, Lagast J. An overview of oral bioavailability enhancement through self-emulsifying drug delivery systems. Expert Opin Drug Deliv. 2025;22(5):659\u201371.","journal-title":"Expert Opin Drug Deliv"},{"issue":"16","key":"10841_CR88","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.2174\/0113816128296705240327065131","volume":"30","author":"A Chauhan","year":"2024","unstructured":"Chauhan A, Kamal R, Mishra R, Shekho D, Awasthi A. A Comprehensive Guide to the Development, Evaluation, and Future Prospects of Self-nanoemulsifying Drug Delivery Systems for Poorly Water-soluble Drugs. Curr Pharm Des. 2024;30(16):1211\u20136. https:\/\/doi.org\/10.2174\/0113816128296705240327065131.","journal-title":"Curr Pharm Des"},{"issue":"1\u20132","key":"10841_CR89","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ijpharm.2008.01.004","volume":"355","author":"AA Date","year":"2008","unstructured":"Date AA, Nagarsenker MS. Parenteral microemulsions: an overview. Int J Pharm. 2008;355(1\u20132):19\u201330. https:\/\/doi.org\/10.1016\/j.ijpharm.2008.01.004.","journal-title":"Int J Pharm"},{"issue":"7","key":"10841_CR90","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1517\/17425247.2015.999038","volume":"12","author":"I Cherniakov","year":"2015","unstructured":"Cherniakov I, Domb AJ, Hoffman A. Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects. Expert Opin Drug Deliv. 2015;12(7):1121\u201333. https:\/\/doi.org\/10.1517\/17425247.2015.999038.","journal-title":"Expert Opin Drug Deliv"},{"issue":"11","key":"10841_CR91","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1080\/17425247.2016.1218462","volume":"14","author":"FU Rehman","year":"2017","unstructured":"Rehman FU, Shah KU, Shah SU, Khan IU, Khan GM, Khan A. From nanoemulsions to self-nanoemulsions, with recent advances in self-nanoemulsifying drug delivery systems (SNEDDS). Expert Opin Drug Deliv. 2017;14(11):1325\u201340. https:\/\/doi.org\/10.1080\/17425247.2016.1218462.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"10841_CR92","first-page":"21","volume":"3","author":"HA Makadia","year":"2013","unstructured":"Makadia HA, Bhatt AY, Parmar RB, Paun JS, Tank H. Self-nano emulsifying drug delivery system (SNEDDS): future aspects. Asian J Pharm Res. 2013;3(1):21\u20137.","journal-title":"Asian J Pharm Res"},{"key":"10841_CR93","first-page":"555","volume-title":"Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological","author":"M Pradhan","year":"2020","unstructured":"Pradhan M, Parihar AK, Singh D, Singh MR. Quality by design and formulation optimization using statistical tools for safe and efficient bioactive loading. In: Singh MR, Singh D, Kanwar JR, Chauhan NS, editors. Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological. Agents: Academic; 2020. pp. 555\u201394."},{"issue":"7","key":"10841_CR94","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1080\/1061186X.2025.2469751","volume":"33","author":"A Jindal","year":"2025","unstructured":"Jindal A, Kumar Sharma P, Kumar A. Self-nanoemulsifying drug delivery system (SNEDDS) as nano-carrier framework for permeability modulating approaches of BCS class III drug. J Drug Target. 2025;33(7):1067\u201387.","journal-title":"J Drug Target"},{"key":"10841_CR95","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jconrel.2023.06.024","volume":"360","author":"KS Kim","year":"2023","unstructured":"Kim KS, Na K, Bae YH. Nanoparticle oral absorption and its clinical translational potential. J Control Release. 2023;360:149\u201362. https:\/\/doi.org\/10.1016\/j.jconrel.2023.06.024.","journal-title":"J Control Release"},{"issue":"1","key":"10841_CR96","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/cimb48010063","volume":"48","author":"J Yu","year":"2026","unstructured":"Yu J, Wang P, Bei Z, Tan L, Wang J, Qin G, et al. Recent Advances in Oral Drug Delivery Systems for BCS III Drugs. Curr Issues Mol Biol. 2026;48(1):63. https:\/\/doi.org\/10.3390\/cimb48010063.","journal-title":"Curr Issues Mol Biol"},{"key":"10841_CR97","doi-asserted-by":"publisher","unstructured":"Saeed MD, Shah KU, Fahad M, Shah SU, Badshah SF, Shah H, et al. Self-nanoemulsifying drug delivery system for nebulization: fabrication and evaluation for systemic delivery of atorvastatin. Naunyn Schmiedebergs Arch Pharmacol. 2024;1\u201314. https:\/\/doi.org\/10.1007\/s00210-024-03494-w.","DOI":"10.1007\/s00210-024-03494-w"},{"key":"10841_CR98","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/B978-0-443-13870-6.00005-2","volume-title":"Micro and nanoemulsions in colorectal cancer","author":"B Basu","year":"2024","unstructured":"Basu B, Garala K, Dutta A, Joshi R, Prajapati BG, Mukherjee S, et al. Micro and nanoemulsions in colorectal cancer. Colorectal Cancer: Elsevier; 2024. pp. 259\u201386."},{"key":"10841_CR99","doi-asserted-by":"publisher","DOI":"10.2174\/0124681873314206241023034855","author":"N Shanthi","year":"2024","unstructured":"Shanthi N, Arora K, Pant H, Soni K, Gupta G, Chandra G, et al. Fortifying SNEDDS with Hybrid Technologies: Present and Future Prospects. Curr Nanomed. 2024. https:\/\/doi.org\/10.2174\/0124681873314206241023034855.","journal-title":"Curr Nanomed"},{"key":"10841_CR100","doi-asserted-by":"publisher","first-page":"105435","DOI":"10.1016\/j.jddst.2024.105435","volume":"93","author":"J Natesh","year":"2024","unstructured":"Natesh J, Mukhlis Y, Ramasamy S, Mondal P, Kaur B, Meeran SM. Development of a self-nanoemulsifying drug delivery system of diindolylmethane for enhanced bioaccessibility, bioavailability and anti-breast cancer efficacy. J Drug Deliv Sci Technol. 2024;93:105435.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"10841_CR101","first-page":"65","volume":"274","author":"TD Nandgude","year":"2004","unstructured":"Nandgude TD, Jadhavrao JN, Jawlekar AR, Poddar SS. Development of self-micro emulsifying drug delivery system based solid dosage form containing simvastatin. Int J Pharm. 2004;274(1):65\u201373.","journal-title":"Int J Pharm"},{"issue":"42","key":"10841_CR102","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.2174\/1381612827666210526091825","volume":"27","author":"FA de Reis","year":"2021","unstructured":"de Reis FA, de Araujo Rego MY, Rocha RI, Guedes BP, de Medeiros Ramalho GG, de Medeiros Cavalcanti IM. A General Approach on Surfactants Use and Properties in Drug Delivery Systems. Curr Pharm Des. 2021;27(42):4300\u201314. https:\/\/doi.org\/10.2174\/1381612827666210526091825.","journal-title":"Curr Pharm Des"},{"issue":"9","key":"10841_CR103","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.3390\/polym13091378","volume":"13","author":"N Dib","year":"2021","unstructured":"Dib N, L\u00e9pori CM, Correa NM, Silber JJ, Falcone RD, Garc\u00eda-R\u00edo L. Biocompatible solvents and ionic liquid-based surfactants as sustainable components to formulate environmentally friendly organized systems. Polymers. 2021;13(9):1378. https:\/\/doi.org\/10.3390\/polym13091378.","journal-title":"Polymers"},{"issue":"5","key":"10841_CR104","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ejps.2005.08.001","volume":"26","author":"N Sadurni","year":"2005","unstructured":"Sadurni N, Solans C, Azemar N, Garcia-Celma MJ. Studies on the formation of O\/W nano-emulsions, by low-energy emulsification methods, suitable for pharmaceutical applications. Eur J Pharm Sci. 2005;26(5):438\u201345. https:\/\/doi.org\/10.1016\/j.ejps.2005.08.001.","journal-title":"Eur J Pharm Sci"},{"issue":"1\u20132","key":"10841_CR105","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijpharm.2008.06.021","volume":"362","author":"SD Mandawgade","year":"2008","unstructured":"Mandawgade SD, Sharma S, Pathak S, Patravale VB. Development of SMEDDS using natural lipophile: application to beta-Artemether delivery. Int J Pharm. 2008;362(1\u20132):179\u201383. https:\/\/doi.org\/10.1016\/j.ijpharm.2008.06.021.","journal-title":"Int J Pharm"},{"issue":"2","key":"10841_CR106","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1023\/b:pham.0000016235.32639.23","volume":"21","author":"RG Strickley","year":"2004","unstructured":"Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res. 2004;21(2):201\u201330. https:\/\/doi.org\/10.1023\/b:pham.0000016235.32639.23.","journal-title":"Pharm Res"},{"key":"10841_CR107","doi-asserted-by":"publisher","unstructured":"Chine S, Inavolu Srinivasa C, Maddela S, Sakhare D, Mankar D, Gharat P, Formulation and evaluation of self-nanoemulsifying drug delivery systems. 2023;12:4492\u2013503 https:\/\/doi.org\/10.31838\/ecb\/2023.12.si6.397","DOI":"10.31838\/ecb\/2023.12.si6.397"},{"issue":"3","key":"10841_CR108","doi-asserted-by":"publisher","first-page":"205","DOI":"10.29090\/psa.2020.03.019.0121","volume":"47","author":"B Morakul","year":"2020","unstructured":"Morakul B. Self-nanoemulsifying drug delivery systems (SNEDDS): an advancement technology for oral drug delivery. Pharm Sci Asia. 2020;47(3):205\u201320. https:\/\/doi.org\/10.29090\/psa.2020.03.019.0121.","journal-title":"Pharm Sci Asia"},{"issue":"1","key":"10841_CR109","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s13346-022-01193-8","volume":"13","author":"C Rathore","year":"2023","unstructured":"Rathore C, Hemrajani C, Sharma AK, Gupta PK, Jha NK, Aljabali AAA, et al. Self-nanoemulsifying drug delivery system (SNEDDS) mediated improved oral bioavailability of thymoquinone: optimization, characterization, pharmacokinetic, and hepatotoxicity studies. Drug Deliv Transl Res. 2023;13(1):292\u2013307. https:\/\/doi.org\/10.1007\/s13346-022-01193-8.","journal-title":"Drug Deliv Transl Res"},{"issue":"5","key":"10841_CR110","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1208\/s12249-016-0632-x","volume":"18","author":"A Khattab","year":"2017","unstructured":"Khattab A, Hassanin L, Zaki N. Self-Nanoemulsifying Drug Delivery System of Coenzyme (Q10) with Improved Dissolution, Bioavailability, and Protective Efficiency on Liver Fibrosis. AAPS PharmSciTech. 2017;18(5):1657\u201372. https:\/\/doi.org\/10.1208\/s12249-016-0632-x.","journal-title":"AAPS PharmSciTech"},{"key":"10841_CR111","doi-asserted-by":"publisher","unstructured":"Bamanna A, Rajora A, Nagpal K. Enhancing microemulsion based therapeutic drug delivery: exploring surfactants, co-surfactants, and quality by design strategies within pseudo-ternary phase diagrams. Crit Reviews\u2122 Therapeutic Drug Carrier Syst. https:\/\/doi.org\/10.1615\/CritRevTherDrugCarrierSyst.2024053427","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2024053427"},{"key":"10841_CR112","doi-asserted-by":"publisher","first-page":"102227","DOI":"10.1016\/j.cis.2020.102227","volume":"283","author":"M Jalali-Jivan","year":"2020","unstructured":"Jalali-Jivan M, Garavand F, Jafari SM. Microemulsions as nano-reactors for the solubilization, separation, purification and encapsulation of bioactive compounds. Adv Colloid Interface Sci. 2020;283:102227. https:\/\/doi.org\/10.1016\/j.cis.2020.102227.","journal-title":"Adv Colloid Interface Sci"},{"key":"10841_CR113","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jddst.2018.01.013","volume":"44","author":"J Rohrer","year":"2018","unstructured":"Rohrer J, Zupan\u010di\u010d O, Het\u00e9nyi G, Kurpiers M, Bernkop-Schn\u00fcrch A. Design and evaluation of SEDDS exhibiting high emulsifying properties. J Drug Deliv Sci Technol. 2018;44:366\u201372. https:\/\/doi.org\/10.1016\/j.jddst.2018.01.013.","journal-title":"J Drug Deliv Sci Technol"},{"key":"10841_CR114","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.addr.2018.10.014","volume":"142","author":"I Nardin","year":"2019","unstructured":"Nardin I, Kollner S. Successful development of oral SEDDS: screening of excipients from the industrial point of view. Adv Drug Deliv Rev. 2019;142:128\u201340. https:\/\/doi.org\/10.1016\/j.addr.2018.10.014.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10841_CR115","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ejpb.2009.03.001","volume":"72","author":"P Balakrishnan","year":"2009","unstructured":"Balakrishnan P, Lee BJ, Oh DH, Kim JO, Hong MJ, Jee JP, et al. Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug delivery system (SEDDS). Eur J Pharm Biopharm. 2009;72(3):539\u201345. https:\/\/doi.org\/10.1016\/j.ejpb.2009.03.001.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1\u20132","key":"10841_CR116","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ijpharm.2012.04.001","volume":"431","author":"AM Villar","year":"2012","unstructured":"Villar AM, Naveros BC, Campmany AC, Trenchs MA, Rocabert CB, Bellowa LH. Design and optimization of self-nanoemulsifying drug delivery systems (SNEDDS) for enhanced dissolution of gemfibrozil. Int J Pharm. 2012;431(1\u20132):161\u201375. https:\/\/doi.org\/10.1016\/j.ijpharm.2012.04.001.","journal-title":"Int J Pharm"},{"issue":"6","key":"10841_CR117","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.addr.2007.10.012","volume":"60","author":"CM O\u2019Driscoll","year":"2008","unstructured":"O\u2019Driscoll CM, Griffin BT. Biopharmaceutical challenges associated with drugs with low aqueous solubility\u2013the potential impact of lipid-based formulations. Adv Drug Deliv Rev. 2008;60(6):617\u201324. https:\/\/doi.org\/10.1016\/j.addr.2007.10.012.","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"10841_CR118","first-page":"1734","volume":"2","author":"P Saikia","year":"2024","unstructured":"Saikia P, Das A, Chutia A. Nano tech for better drugs: Exploring the advantages of self-nano emulsifying drug delivery systems. Int J Pharm Sci. 2024;2(7):1734\u201352.","journal-title":"Int J Pharm Sci"},{"issue":"8","key":"10841_CR119","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3109\/10717544.2011.604686","volume":"18","author":"B Singh","year":"2011","unstructured":"Singh B, Khurana L, Bandyopadhyay S, Kapil R, Katare OO. Development of optimized self-nano-emulsifying drug delivery systems (SNEDDS) of carvedilol with enhanced bioavailability potential. Drug Deliv. 2011;18(8):599\u2013612. https:\/\/doi.org\/10.3109\/10717544.2011.604686.","journal-title":"Drug Deliv"},{"key":"10841_CR120","doi-asserted-by":"publisher","first-page":"611322","DOI":"10.3389\/fped.2021.611322","volume":"9","author":"M Faisal","year":"2021","unstructured":"Faisal M, Cawello W, Laeer S, Consortium L. Clinical Pharmacokinetics of Enalapril and Enalaprilat in Pediatric Patients-A Systematic Review. Front Pediatr. 2021;9:611322. https:\/\/doi.org\/10.3389\/fped.2021.611322.","journal-title":"Front Pediatr"},{"key":"10841_CR121","volume-title":"Enalapril. StatPearls","author":"A Faruqi","year":"2024","unstructured":"Faruqi A, Patel P, Jain A. Enalapril. StatPearls. Treasure Island (FL): StatPearls Publishing; 2024."},{"key":"10841_CR122","unstructured":"Ammar AA, Ramadan AA, Hassan DH, Younis MK. Preparation and in-vitro characterization of self-nanoemulsifying drug delivery systems of enalapril. Inventi Impact: NDDS. 2016;(3):129\u201338."},{"issue":"13","key":"10841_CR123","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.jacc.2018.01.058","volume":"71","author":"FH Messerli","year":"2018","unstructured":"Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use? J Am Coll Cardiol. 2018;71(13):1474\u201382. https:\/\/doi.org\/10.1016\/j.jacc.2018.01.058.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10841_CR124","doi-asserted-by":"publisher","first-page":"396","DOI":"10.2174\/138920012800166544","volume":"13","author":"Y Lu","year":"2012","unstructured":"Lu Y, Qi J, Wu W. Absorption, disposition and pharmacokinetics of nanoemulsions. Curr Drug Metab. 2012;13(4):396\u2013417. https:\/\/doi.org\/10.2174\/138920012800166544.","journal-title":"Curr Drug Metab"},{"issue":"11","key":"10841_CR125","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/cpdd.930","volume":"10","author":"R Hermann","year":"2021","unstructured":"Hermann R, Gundlach K, Seiler D. Mechanistic Considerations About an Unexpected Ramipril Drug-Drug Interaction in the Development of a Triple Fixed\u2010Dose Combination Product Containing Ramipril, Amlodipine, and Atorvastatin. Clin Pharmacol Drug Dev. 2021;10(11):1307\u201315. https:\/\/doi.org\/10.1002\/cpdd.930.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"10841_CR126","doi-asserted-by":"publisher","first-page":"126","DOI":"10.22159\/ajpcr.2021.v14i7.42003","volume":"14","author":"N Jayapal","year":"2021","unstructured":"Jayapal N, Vamshi V. Formulation and in vivo evaluation of self-nanoemulsifying drug delivery system of ramipril in Wistar rats. Asian J Pharm Clin Res. 2021;14(7):126\u201336.","journal-title":"Asian J Pharm Clin Res"},{"issue":"9","key":"10841_CR127","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3390\/ph15091120","volume":"15","author":"AA Shahba","year":"2022","unstructured":"Shahba AA, Sherif AY, Elzayat EM, Kazi M. Combined Ramipril and Black Seed Oil Dosage Forms Using Bioactive Self-Nanoemulsifying Drug Delivery Systems (BIO-SNEDDSs). Pharmaceuticals (Basel). 2022;15(9):1120. https:\/\/doi.org\/10.3390\/ph15091120.","journal-title":"Pharmaceuticals (Basel)"},{"key":"10841_CR128","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.2147\/IJN.S203311","volume":"14","author":"KF Alhasani","year":"2019","unstructured":"Alhasani KF, Kazi M, Ibrahim MA, Shahba AA, Alanazi FK. Self-nanoemulsifying ramipril tablets: a novel delivery system for the enhancement of drug dissolution and stability. Int J Nanomed. 2019;14:5435\u201348. https:\/\/doi.org\/10.2147\/IJN.S203311.","journal-title":"Int J Nanomed"},{"key":"10841_CR129","doi-asserted-by":"publisher","unstructured":"Alhasani KF, Kazi M, Ibrahim MA, Shahba AA, Alanazi FK. Self-nanoemulsifying ramipril tablets: a novel delivery system for the enhancement of drug dissolution and stability. Int J Nanomed. 2019;5435\u201348. https:\/\/doi.org\/10.2147\/IJN.S203311.","DOI":"10.2147\/IJN.S203311"},{"issue":"1","key":"10841_CR130","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3892\/or.2020.7607","volume":"44","author":"N Fujita","year":"2020","unstructured":"Fujita N, Fujita K, Iwama H, Kobara H, Fujihara S, Chiyo T, et al. Antihypertensive drug telmisartan suppresses the proliferation of gastric cancer cells in vitro and in vivo. Oncol Rep. 2020;44(1):339\u201348. https:\/\/doi.org\/10.3892\/or.2020.7607.","journal-title":"Oncol Rep"},{"issue":"2","key":"10841_CR131","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3892\/mmr.2020.11144","volume":"22","author":"H Kobara","year":"2020","unstructured":"Kobara H, Fujihara S, Iwama H, Matsui T, Fujimori A, Chiyo T, et al. Antihypertensive drug telmisartan inhibits cell proliferation of gastrointestinal stromal tumor cells in vitro. Mol Med Rep. 2020;22(2):1063\u201371. https:\/\/doi.org\/10.3892\/mmr.2020.11144.","journal-title":"Mol Med Rep"},{"issue":"2","key":"10841_CR132","doi-asserted-by":"publisher","first-page":"112","DOI":"10.4103\/2230-973X.82431","volume":"1","author":"J Patel","year":"2011","unstructured":"Patel J, Kevin G, Patel A, Raval M, Sheth N. Design and development of a self-nanoemulsifying drug delivery system for telmisartan for oral drug delivery. Int J Pharm Investig. 2011;1(2):112\u20138. https:\/\/doi.org\/10.4103\/2230-973X.82431.","journal-title":"Int J Pharm Investig"},{"issue":"3","key":"10841_CR133","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10157-021-02153-1","volume":"26","author":"S Ohno","year":"2022","unstructured":"Ohno S, Ishii A, Yanagita M, Yokoi H. Calcium channel blocker in patients with chronic kidney disease. Clin Exp Nephrol. 2022;26(3):207\u201315. https:\/\/doi.org\/10.1007\/s10157-021-02153-1.","journal-title":"Clin Exp Nephrol"},{"key":"10841_CR134","unstructured":"Buddhadev SS, Garala KC, Nariya M, Rahamathulla M. Solid self nanoemulsifying drug delivery system as carrier for the enhancement of bioavailability of Benidipine with Telmisartan."},{"issue":"8","key":"10841_CR135","doi-asserted-by":"publisher","first-page":"e087983","DOI":"10.1136\/bmjopen-2024-087983","volume":"14","author":"K Andresen","year":"2024","unstructured":"Andresen K, Cutting E, Apostolopoulos D, Evans AH, Oakley L, Dayimu A, et al. Trial to assess the tolerability of using felodipine to upregulate autophagy as a treatment of Huntington\u2019s disease (FELL-HD): a phase II, single-centre, open-label, dose-finding trial protocol. BMJ open. 2024;14(8):e087983.","journal-title":"BMJ open"},{"issue":"1","key":"10841_CR136","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s42004-023-00893-7","volume":"6","author":"YP Jiang","year":"2023","unstructured":"Jiang YP, Fang XH, Wang Q, Huo JZ, Liu YY, Wang XR, et al. Near-infrared magnetic core-shell nanoparticles based on lanthanide metal-organic frameworks as a ratiometric felodipine sensing platform. Commun Chem. 2023;6(1):96. https:\/\/doi.org\/10.1038\/s42004-023-00893-7.","journal-title":"Commun Chem"},{"issue":"6","key":"10841_CR137","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1515\/tsd-2024-2618","volume":"61","author":"SA Naik","year":"2024","unstructured":"Naik SA, Dcruz CEM, Kumar L, Shirodkar RK. Formulation of Felodipine lipid nanoparticle-loaded oral fast-dissolving films. Tenside Surfactants Detergents. 2024;61(6):568\u201383. https:\/\/doi.org\/10.1515\/tsd-2024-2618.","journal-title":"Tenside Surfactants Detergents"},{"issue":"10","key":"10841_CR138","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3109\/03639045.2013.819884","volume":"40","author":"S Verma","year":"2014","unstructured":"Verma S, Singh SK, Verma PR, Ahsan MN. Formulation by design of felodipine loaded liquid and solid self nanoemulsifying drug delivery systems using Box-Behnken design. Drug Dev Ind Pharm. 2014;40(10):1358\u201370. https:\/\/doi.org\/10.3109\/03639045.2013.819884.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"10841_CR139","doi-asserted-by":"publisher","first-page":"18","DOI":"10.21608\/ajps.2018.46619","volume":"57","author":"A Shaaban","year":"2018","unstructured":"Shaaban A. Formulation, characterization and In-Vitro release of oral felodipine self-nanoemulsifying drug delivery Systems. Al-Azhar J Pharm Sci. 2018;57(1):18\u201351.","journal-title":"Al-Azhar J Pharm Sci"},{"key":"10841_CR140","doi-asserted-by":"crossref","unstructured":"Basu P, Ramasubban S. Antihypertensive therapy. Principles and Practice of Neurocritical Care. Springer; 2024. pp. 299\u2013308.","DOI":"10.1007\/978-981-99-8059-8_21"},{"key":"10841_CR141","first-page":"092524314408","volume":"2024","author":"H Choi","year":"2024","unstructured":"Choi H, Chou SH, Durcruet A, Kimberly W, Macdonald RL, Rabinstein AA. STRIVE-ON: Safety and ToleRability of GTX-104 (Nimodipine Injection for IV Infusion) ComparEd with Oral Nimodipine in Patients Hospitalized for Aneurysmal Subarachnoid Hemorrhage (aSAH): a Prospective, Randomized Trial (STRIVE-ON). medRxiv. 2024;2024:092524314408.","journal-title":"medRxiv"},{"key":"10841_CR142","doi-asserted-by":"publisher","unstructured":"Yi T, Zhang J. Effects of hydrophilic carriers on structural transitions and in vitro properties of solid self-microemulsifying drug delivery systems. Pharmaceutics. 2019;11(6). https:\/\/doi.org\/10.3390\/pharmaceutics11060267.","DOI":"10.3390\/pharmaceutics11060267"},{"issue":"1","key":"10841_CR143","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s43094-024-00653-x","volume":"10","author":"M Kumar","year":"2024","unstructured":"Kumar M, Chawla PA, Faruk A, Chawla V. Solid self-nanoemulsifying drug delivery systems of nimodipine: development and evaluation. Future J Pharm Sci. 2024;10(1):87.","journal-title":"Future J Pharm Sci"},{"key":"10841_CR144","doi-asserted-by":"publisher","unstructured":"Reddy SS, Suresh G. A Self nanoemulsifying drug delivery system for improvement in oral bioavailability of nimodipine: in vivo evaluation. Syst (BCS). 2:3. https:\/\/doi.org\/10.13040\/IJPSR.0975-8232.12\/11\/.5943-48","DOI":"10.13040\/IJPSR.0975-8232.12\/11\/.5943-48"},{"issue":"7","key":"10841_CR145","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3109\/03639045.2014.925918","volume":"41","author":"G Surampalli","year":"2015","unstructured":"Surampalli G, Patil BKN. Corroboration of naringin effects on the intestinal absorption and pharmacokinetic behavior of candesartan cilexetil solid dispersions using in-situ rat models. Drug Dev Ind Pharm. 2015;41(7):1057\u201365. https:\/\/doi.org\/10.3109\/03639045.2014.925918.","journal-title":"Drug Dev Ind Pharm"},{"issue":"2","key":"10841_CR146","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jconrel.2010.10.013","volume":"149","author":"F Gao","year":"2011","unstructured":"Gao F, Zhang Z, Bu H, Huang Y, Gao Z, Shen J, et al. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism. J Control Release. 2011;149(2):168\u201374. https:\/\/doi.org\/10.1016\/j.jconrel.2010.10.013.","journal-title":"J Control Release"},{"issue":"5","key":"10841_CR147","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s13346-016-0297-8","volume":"6","author":"S Jain","year":"2016","unstructured":"Jain S, Reddy VA, Arora S, Patel K. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability. Drug Deliv Transl Res. 2016;6(5):498\u2013510. https:\/\/doi.org\/10.1007\/s13346-016-0297-8.","journal-title":"Drug Deliv Transl Res"},{"issue":"9","key":"10841_CR148","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1080\/07373937.2011.652268","volume":"30","author":"RM Martins","year":"2012","unstructured":"Martins RM, Machado MO, Pereira SV, Nosari ABFL, Tacon LA, Freitas LAP. Microparticulated Hydrochlorothiazide Solid Dispersion: Enhancing Dissolution Properties via Spray Drying. Drying Technol. 2012;30(9):959\u201367. https:\/\/doi.org\/10.1080\/07373937.2011.652268.","journal-title":"Drying Technol"},{"key":"10841_CR149","doi-asserted-by":"publisher","first-page":"102320","DOI":"10.1016\/j.jddst.2021.102320","volume":"61","author":"MB Zewail","year":"2021","unstructured":"Zewail MB, El-Gizawy SA, Osman MA, Haggag YA. Preparation and In vitro characterization of a novel self-nano emulsifying drug delivery system for a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide. J Drug Deliv Sci Technol. 2021;61:102320. https:\/\/doi.org\/10.1016\/j.jddst.2021.102320.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"5","key":"10841_CR150","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1159\/000168471","volume":"12","author":"RW van Olden","year":"1992","unstructured":"van Olden RW, van Meyel JJ, Gerlag PG. Acute and long-term effects of therapy with high-dose furosemide in chronic hemodialysis patients. Am J Nephrol. 1992;12(5):351\u20136. https:\/\/doi.org\/10.1159\/000168471.","journal-title":"Am J Nephrol"},{"issue":"4","key":"10841_CR151","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/ph17040500","volume":"17","author":"S Gul","year":"2024","unstructured":"Gul S, Sridhar SB, Jalil A, Akhlaq M, Arshad MS, Sarwar HS, et al. Solid Self-Nanoemulsifying Drug Delivery Systems of Furosemide: In Vivo Proof of Concept for Enhanced Predictable Therapeutic Response. Pharmaceuticals (Basel). 2024;17(4):500. https:\/\/doi.org\/10.3390\/ph17040500.","journal-title":"Pharmaceuticals (Basel)"},{"key":"10841_CR152","unstructured":"Owoyemi BCD. Supramolecular synthesis and characterization of new multicomponent forms of fluconazole. 2020."},{"issue":"4","key":"10841_CR153","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11906-016-0636-7","volume":"18","author":"L Malha","year":"2016","unstructured":"Malha L, Mann SJ. Loop Diuretics in the Treatment of Hypertension. Curr Hypertens Rep. 2016;18(4):27. https:\/\/doi.org\/10.1007\/s11906-016-0636-7.","journal-title":"Curr Hypertens Rep"},{"issue":"1","key":"10841_CR154","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/s41598-020-79940-5","volume":"11","author":"L Dalal","year":"2021","unstructured":"Dalal L, Allaf AW, El-Zein H. Formulation and in vitro evaluation of self-nanoemulsifying liquisolid tablets of furosemide. Sci Rep. 2021;11(1):1315. https:\/\/doi.org\/10.1038\/s41598-020-79940-5.","journal-title":"Sci Rep"},{"issue":"4","key":"10841_CR155","first-page":"291","volume":"8","author":"K Madhavi","year":"2016","unstructured":"Madhavi K, Shikha A, Yadav JK. Self-Nano emulsifying drug delivery system of ramipril: formulation and in vitro evaluation. Int J Pharm Pharm Sci. 2016;8(4):291\u20136.","journal-title":"Int J Pharm Pharm Sci"},{"issue":"4","key":"10841_CR156","doi-asserted-by":"publisher","first-page":"155932582098219","DOI":"10.1177\/1559325820982190","volume":"18","author":"H Murad","year":"2020","unstructured":"Murad H, Ahmed O, Ghabrah T, Gari M. Telmisartan Self-Nanoemulsifying Drug Delivery System, Compared With Standard Telmisartan, More Effectively Improves Hepatic Fibrosis in Rats. Dose Response. 2020;18(4):1559325820982190. https:\/\/doi.org\/10.1177\/1559325820982190.","journal-title":"Dose Response"},{"issue":"1","key":"10841_CR157","doi-asserted-by":"publisher","first-page":"167","DOI":"10.5599\/admet.2022","volume":"12","author":"AZG Al Ashmawy","year":"2024","unstructured":"Al Ashmawy AZG, Alyami MH, Eissa NG, Balata GF, El Nahas HM. Oral bioavailability enhancement of doxazosin mesylate: Nanosuspension versus self-nanoemulsifying drug delivery systems. ADMET DMPK. 2024;12(1):167\u201376. https:\/\/doi.org\/10.5599\/admet.2022.","journal-title":"ADMET DMPK"},{"key":"10841_CR158","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jconrel.2023.08.024","volume":"362","author":"O Zupancic","year":"2023","unstructured":"Zupancic O, Kushwah V, Paudel A. Pancreatic lipase digestion: The forgotten barrier in oral administration of lipid-based delivery systems? J Control Release. 2023;362:381\u201395. https:\/\/doi.org\/10.1016\/j.jconrel.2023.08.024.","journal-title":"J Control Release"},{"issue":"12","key":"10841_CR159","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3390\/pharmaceutics12121194","volume":"12","author":"AB Buya","year":"2020","unstructured":"Buya AB, Beloqui A, Memvanga PB, Preat V. Self-Nano-Emulsifying Drug-Delivery Systems: From the Development to the Current Applications and Challenges in Oral Drug Delivery. Pharmaceutics. 2020;12(12):1194. https:\/\/doi.org\/10.3390\/pharmaceutics12121194.","journal-title":"Pharmaceutics"},{"key":"10841_CR160","doi-asserted-by":"crossref","unstructured":"O\u2019Shea JP, O\u2019Driscoll CM, Griffin BT. Lipid-based formulations. Oral Drug Delivery for Modified Release Formulations. 2022:137\u2009\u2013\u200960.","DOI":"10.1002\/9781119772729.ch8"},{"issue":"5","key":"10841_CR161","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.3390\/jcm12051799","volume":"12","author":"Y Sethi","year":"2023","unstructured":"Sethi Y, Patel N, Kaka N, Kaiwan O, Kar J, Moinuddin A, et al. Precision Medicine and the future of Cardiovascular Diseases: A Clinically Oriented Comprehensive Review. J Clin Med. 2023;12(5):1799. https:\/\/doi.org\/10.3390\/jcm12051799.","journal-title":"J Clin Med"},{"issue":"6","key":"10841_CR162","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.apsb.2013.10.001","volume":"3","author":"S Kalepu","year":"2013","unstructured":"Kalepu S, Manthina M, Padavala V. Oral lipid-based drug delivery systems\u2013an overview. Acta Pharm Sinica B. 2013;3(6):361\u201372.","journal-title":"Acta Pharm Sinica B"},{"issue":"8","key":"10841_CR163","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1208\/s12249-018-1188-8","volume":"19","author":"V Patel","year":"2018","unstructured":"Patel V, Lalani R, Bardoliwala D, Ghosh S, Misra A. Lipid-Based Oral Formulation Strategies for Lipophilic Drugs. AAPS PharmSciTech. 2018;19(8):3609\u201330. https:\/\/doi.org\/10.1208\/s12249-018-1188-8.","journal-title":"AAPS PharmSciTech"},{"key":"10841_CR164","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.addr.2016.04.007","volume":"101","author":"OM Feeney","year":"2016","unstructured":"Feeney OM, Crum MF, McEvoy CL, Trevaskis NL, Williams HD, Pouton CW, et al. 50 years of oral lipid-based formulations: provenance, progress and future perspectives. Adv Drug Deliv Rev. 2016;101:167\u201394.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10841_CR165","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nrd2197","volume":"6","author":"CJ Porter","year":"2007","unstructured":"Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231\u201348. https:\/\/doi.org\/10.1038\/nrd2197.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10841_CR166","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1007\/s11095-013-1126-0","volume":"30","author":"HD Williams","year":"2013","unstructured":"Williams HD, Trevaskis NL, Yeap YY, Anby MU, Pouton CW, Porter CJ. Lipid-Based Formulations and Drug Supersaturation: Harnessing the Unique Benefits of the Lipid Digestion\/Absorption Pathway: Williams et al. Pharm Res. 2013;30(12):2976\u201392.","journal-title":"Pharm Res"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-026-10841-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-026-10841-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-026-10841-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:05:22Z","timestamp":1789059922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-026-10841-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":166,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["10841"],"URL":"https:\/\/doi.org\/10.1007\/s12265-026-10841-0","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"28 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.","order":3,"name":"Ethics","label":"Financial Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical Trial Number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that no paper mills or artificial intelligence were used.","order":5,"name":"Ethics","label":"AI Declaration","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"115"}}